While the recreational side of the industry has received most of the coverage since marijuana was legalized in Canada last year, medical cannabis has remained a strong focus for many companies.
A new documentary covering the possible applications of cannabis oil for pediatric patients will be screened in eight Canadian cities courtesy of Relevium Technologies Inc. (TSX.V: RLV; OTCQB: RLLVF).
Relevium will screen Weed The People — a documentary from Ricki Lake and Abby Epstein — on Jan. 15 in Toronto, Vancouver, Montreal, Ottawa, Calgary, Edmonton, Winnipeg, and Halifax.
The documentary is being released in conjunction with CannaKids, which just granted an exclusive license to Relevium for medical cannabis branding and research into pediatric applications.
Relevium currently operates in the cannabis industry through two wholly-owned subsidiaries: Montreal-based Biocannabix Health Corporation for Canadian operations and Florida-based BGX E-Health LLC for U.S. sales.
In a press release about the Weed The People screening, Chief Executive Officer Aurelio Useche stated that the documentary validates the Cannabis Act legalizing marijuana nationwide and also further commented:
Research studies into new medical applications for cannabis have been announced regularly since the Cannabis Act eased restrictions on how marijuana can be used. A few of the highlights from October to December of 2018 include:
- Aphria (TSX: APH) recruited a new Director of Research to conduct clinical trials of medical marijuana last year.
- Cronos Group Inc. (NASDAQ: CRON; TSX: CRON) entered into a research agreement with an Israeli company to study using cannabis for treating skin disorders.
- Canntab Therapeutics Limited (CSE: PILL) is funding a clinical trial with the University of British Columbia to study using cannabis rather than opioids for post-surgical pain management.
- Veritas Pharma Inc. (CSE: VRT) recently began human trials in Puerto Rico for using marijuana as part of a pain management plan for patients.
The opinions provided in this article are those of the author and do not constitute investment advice. Readers should assume that the author and/or employees of Grizzle hold positions in the company or companies mentioned in the article. For more information, please see our Content Disclaimer.